Answers are grounded in this paper and cite their sources.
Eighty-four percent of nonpalpable prostate cancers diagnosed by screening techniques are significant tumors and warrant definitive therapy. However, 16% are insignificant. Serum PSA level, PSA density, and needle biopsy pathologic findings are accurate predictors of tumor extent. It may be reasonable to follow up some patients whose tumors are most likely insignificant with serial PSA measurements and repeated biopsies.
No takes yet. Share an insight, caveat, or question.
Jonathan I. Epstein (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: